[1] The Polaris Observatory Collaborators. Global prevalence, treatment, and prevention of hepatitis B virus infection in 2016: a modelling study. Lancet Gastroenterol Hepatol 2018;3(6):383 − 403. http://dx.doi.org/10.1016/S2468-1253(18)30056-6CrossRef
[2] Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: Cancer J Clin 2018;68(6):394 − 424. http://dx.doi.org/10.3322/caac.21492CrossRef
[3] Zhang Q, Miao N, Zheng H, Sun XJ, Yin ZD, Wang FZ. Incidence by age and region of hepatitis B reported in China from 2005 to 2016. Chin J Vaccin Immun 2018; 24(2): 121-6. http://d.wanfangdata.com.cn/periodical/zgjhmy201802001. (In Chinese).http://d.wanfangdata.com.cn/periodical/zgjhmy201802001
[4] WHO. Global health sector strategy on viral hepatitis 2016-2021. http://www.who.int/hepatitis/strategy2016-2021/ghss-hep/en/.http://www.who.int/hepatitis/strategy2016-2021/ghss-hep/en/
[5] Cui FQ, Shen LP, Li L, Wang HQ, Wang FZ, Bi SL, et al. Prevention of chronic hepatitis B after 3 decades of escalating vaccination policy, China. Emerg Infect Dis 2017;23(5):765 − 72. http://dx.doi.org/10.3201/eid2305.161477CrossRef
[6] World Health Organization. Hepatitis B: WHO Fact Sheet, July 2020. https://www.who.int/en/news-room/fact-sheets/detail/hepatitis-b. [2020-07-02]. https://www.who.int/en/news-room/fact-sheets/detail/hepatitis-b.
[7] Centers for Disease Control and Prevention. Hepatitis B: CDC Fact Sheet, June 2016. https://www.cdc.gov/hepatitis/HBV/PDFs/HepBGeneralFactSheet.pdf. [2020-07-02].https://www.cdc.gov/hepatitis/HBV/PDFs/HepBGeneralFactSheet.pdf.
[8] Ministry of Health of the People’s Republic of China. WS 299-2008 Diagnostic criteria for viral hepatitis B. Beijing: People’s Medical Publishing House, 2009. http://www.csres.com/detail/197791.html. (In Chinese).http://www.csres.com/detail/197791.html
[9] National Health Commission of the People’s Republic of China, Chinese Center for Disease Control and Prevention. The national report of hepatitis B serosurvey of people in China in 2006. Beijing: People’s Medical Publishing House. 2011; p. 1 − 77. https://www.wl.cn/6898778. (In Chinese).https://www.wl.cn/6898778
[10] National Health Commission of the People’s Republic of China. Chinese Center for Disease Control and Prevention. The national report of hepatitis B serosurvey of people aged 1−29 years in China in 2014. Beijing: People’s Medical Publishing House. 2018; p. 1 − 154. https://item.jd.com/12536387.html. (In Chinese).https://item.jd.com/12536387.html
[11] Qin QH, Xie XH, Zhang H, Yao H, Wang Q, Wei P, et al. Monitoring and analysis on maternal HIV, syphilis and hepatitis B serologic testing in Guangxi, 2011−2016. Chin J Health Educ 2018;34(1):10 − 3. http://dx.doi.org/10.16168/j.cnki.issn.1002-9982.2018.01.003 (In Chinese)CrossRef
[12] Wang FZ, Chi PP, Bi SL, Wang F, Zhang S, Zheng H, et al. Study on the risk of spouse infection with hepatitis b virus in patients with acute hepatitis B. Chin J Prev Med 2014;48(8):736 − 7. http://dx.doi.org/10.3760/cma.j.issn.0253-9624.2014.08.017 (In Chinese)CrossRef
[13] Wu WS, Zhao Y, Chen J, Li C, He HY. Incidence trend of acute hepatitis B and related risk factors in Tianjin. Dis Surveill 2014;29(9):729 − 32. http://dx.doi.org/10.3784/j.issn.1003-9961.2014.09.015 (In Chinese)CrossRef
[14] Han YN, Tang Q, Zhu W, Zhang XQ, You LY. Clinical, biochemical, immunological and virological profiles of, and differential diagnosis between, patients with acute hepatitis B and chronic hepatitis B with acute flare. J Gastroenterol Hepatol 2008;23(11):1728 − 33. http://dx.doi.org/10.1111/j.1440-1746.2008.05600.xCrossRef
[15] Dao DY, Hynan LS, Yuan HJ, Sanders C, Balko J, Attar N, et al. Two distinct subtypes of hepatitis B virus-related acute liver failure are separable by quantitative serum immunoglobulin M anti-hepatitis B core antibody and hepatitis B virus DNA levels. Hepatology 2012;55(3):676 − 84. http://dx.doi.org/10.1002/hep.24732CrossRef
[16] Rodella A, Galli C, Terlenghi L, Perandin F, Bonfanti C, Manca N. Quantitative analysis of HBsAg, IgM anti-HBc and anti-HBc avidity in acute and chronic hepatitis B. J Clin Virol 2006;37(3):206 − 12. http://dx.doi.org/10.1016/j.jcv.2006.06.011CrossRef